Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

CNM Au 8

Next Previous
Drug Profile

CNM Au 8

Alternative Names: Clean-surfaced gold nanocrystals; CNM-Au8; Gold nanocrystal suspension; Nanocrystalline gold

Latest Information Update: 11 Sep 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Clene Nanomedicine
  • Class Antiparkinsonians; Eye disorder therapies; Heavy metals
  • Mechanism of Action Energy metabolism stimulants; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Amyotrophic lateral sclerosis
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Amyotrophic lateral sclerosis
  • Phase II/III Multiple sclerosis
  • Phase II Optic nerve disorders; Parkinson's disease
  • Preclinical Rett syndrome

Most Recent Events

  • 04 Sep 2025 Pharmacodynamics and adverse events data from a preclinical study in Parkinson's disease released by Clene Nanomedicine
  • 14 Aug 2025 Clene Nanomedicine plans an ALS Survival Data Type C Meeting with the US FDA in the third quarter of 2025
  • 14 Aug 2025 Clene Nanomedicine plans to file an NDA for Amyotrophic lateral sclerosis under the accelerated approval pathway by the end of 2025

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top